Paltusotine: Who Can Use Oral Acromegaly Treatment?

What does paltusotine approval mean for acromegaly treatment?

Palsonify was among the medicines recommended for approval at the European Medicines Agency's February 2026 committee meeting. Its EU marketing authorization followed on April 23, making this an earlier-year regulatory development rather than a new October approval. The European indication covers medical treatment of adults with acromegaly; availability in individual countries requires separate confirmation. [EMA February meeting highlights](https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-february-2026). [EMA Palsonify assessment](https://www.ema.europa.eu/en/medicines/human/EPAR/palsonify).

Acromegaly develops when excessive growth hormone raises insulin-like growth factor 1, or IGF-1, promoting abnormal tissue growth. Paltusotine activates somatostatin receptors to suppress hormone release and lower IGF-1. Its tablet formulation may appeal to patients managing long-term treatment, but the clinical goal remains sustained disease control. The medicine's convenience must be considered alongside its effectiveness, tolerability and daily administration requirements. [EMA Palsonify assessment](https://www.ema.europa.eu/en/medicines/human/EPAR/palsonify).

How effective was paltusotine in clinical trials?

The FDA's assessment describes two randomized, double-blind phase 3 trials involving 169 adults. In the 111-person study of patients with uncontrolled hormone levels, approximately 56% receiving paltusotine reached normal IGF-1 levels after 24 weeks, compared with 5% receiving placebo. In the 58-person study of patients previously controlled with medical therapy, approximately 83% switching to paltusotine maintained control at 36 weeks, compared with 4% switching to placebo. These percentages describe biochemical control, not cure rates. [FDA efficacy assessment](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-treatment-acromegaly-rare-endocrine-disorder).

The distinction between the populations matters: maintaining control in someone already responding to treatment is a different question from bringing elevated hormone levels into range. Neither trial compared paltusotine directly with continuing active injectable therapy. The findings therefore support its effectiveness against placebo but cannot establish that tablets provide better disease control than injections. Likewise, these relatively short trials do not establish effects on long-term complications or survival. [FDA trial design and results](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-palsonify).

What should patients consider before switching to paltusotine?

Daily treatment introduces practical requirements. The U.S. prescribing information specifies taking paltusotine with water at least six hours after food and at least one hour before the next meal. Clinicians adjust treatment using IGF-1 measurements and tolerability. Some medicines, including proton pump inhibitors used for acid-related conditions, can reduce paltusotine exposure, making medication review important before starting or changing treatment. [Palsonify prescribing information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8a6d2ce0-a621-4ee7-983c-977cd948ff4d&type=display).

Reported adverse effects include diarrhea, abdominal discomfort and nausea. Warnings cover gallstones, high or low blood glucose, slow heart rate or conduction abnormalities, thyroid dysfunction, impaired fat absorption and vitamin B12 deficiency. Monitoring should reflect these risks and the patient's existing conditions. Choosing tablets therefore involves more than avoiding injections: the treatment must fit the person's routine while maintaining hormone control and acceptable tolerability. [Palsonify safety and monitoring information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8a6d2ce0-a621-4ee7-983c-977cd948ff4d&type=display).